Universal Coronavirus mRNA Vaccine (UCV-mRNA)

Infectious Disease/Vaccines

A functionally biosimilar mRNA prophylactic or therapeutic vaccine, or vaccine booster, to enable sustained immunity to current and future SARS-CoV-2 variants.

Project Team

PA
Peter A. Jensen

Institutions

NB
Normax Biomed Limited
IE

Project Status

Clinical Stage
Preclinical
Patent Status
Patent not filed

Funding Opportunity

Opportunity type
Funding requested
$500,000
Funding allocated
$0

Background

The COVID-19 pandemic cost 20 million lives and $28 Trillion dollars. https://normaxbiomed.com/

Project Details

A functionally biosimilar mRNA prophylactic or therapeutic vaccine, or vaccine booster, to enable sustained immunity to current and future SARS-CoV-2 variants. https://normaxbiomed.com/

Project Timeline

  • Universal Coronavirus mRNA Vaccine (UCV-mRNA)

    Required Funding$500,000
    Statusongoing
    Duration6 Months

    UCV-mRNA vaccine design, testing and pre-clinical validation.